Skip to content
bioprospecting
EntityQ2904214· pop 16· linked from 644 articles

bioprospecting

Sign in to save

Also known as biodiversity prospecting

Bioprospecting (also known as biodiversity prospecting) is the exploration of natural sources for small molecules, macromolecules and biochemical and genetic information that could be developed into commercially valuable products for the agricultural, aquaculture, bioremediation, cosmetics, nanotechnology, or pharmaceutical industries. In the pharmaceutical industry, for example, almost one third of all small-molecule drugs approved by the U.S. Food and Drug Administration (FDA) between 1981 and 2014 were either natural products or compounds derived from natural products.

~32 min read

Encyclopedic overview

34 sections
Contents
  • Bioprospecting-derived resources and products
  • Agriculture
  • Bioremediation
  • Cosmetics and personal care
  • Nanotechnology and biosensors
  • Pharmaceuticals
  • Bioprospecting as a discovery strategy
  • Strengths
  • Weaknesses
  • Bioprospecting pitfalls
  • Collection of source material
  • Bioactivity and toxicity testing
  • Identification of mechanism of action
  • Criticism of bioprospecting
  • Criticism of ethnobotanical bioprospecting
  • Cinchona
  • Biopiracy
  • Famous cases of biopiracy
  • The rosy periwinkle
  • The Maya ICBG controversy
  • The neem tree
  • Basmati rice
  • The Enola bean
  • ''Hoodia gordonii''
  • Further cases
  • Legal and political aspects
  • Patent law
  • Convention on Biological Diversity
  • Bioprospecting contracts
  • Traditional knowledge database
  • See also
  • References
  • Bibliography and resources
  • External links

Bioprospecting (also known as biodiversity prospecting) is the exploration of natural sources for small molecules, macromolecules and biochemical and genetic information that could be developed into commercially valuable products for the agricultural, aquaculture, bioremediation, cosmetics, nanotechnology, or pharmaceutical industries. In the pharmaceutical industry, for example, almost one third of all small-molecule drugs approved by the U.S. Food and Drug Administration (FDA) between 1981 and 2014 were either natural products or compounds derived from natural products.

Terrestrial plants, fungi and actinobacteria have been the focus of many past bioprospecting programs, but interest is growing in less explored ecosystems (e.g. seas and oceans, caves and polar regions) and organisms (e.g. extremophiles, tropical corals and necrophages) as a means of identifying new molecules with novel biological activities. Species may be randomly screened for bioactivity or rationally selected and screened based on ecological, ethnobiological, ethnomedical, historical or genomic information.

Excerpted from Wikipedia’s “bioprospecting” article, available under the CC BY-SA 4.0 licence.

Gallery (22)